Role of CD39 (NTPDase-1) in Thromboregulation, Cerebroprotection, and Cardioprotection

ABSTRACT

Blood platelets maintain vascular integrity and promote primary and secondary hemostasis following interruption of vessel continuity. Biochemical or physical damage to coronary, carotid, or peripheral arteries promotes excessive platelet activation and recruitment culminating in vascular occlusion and tissue ischemia. Currently, inadequate therapeutic approaches to stroke and coronary artery disease (CAD) are a public health issue. Following our demonstration of neutrophil leukotriene production from arachidonate released from activated aspirin-treated platelets, we studied interactions among platelets and other blood cells. This led to concepts of transcellular metabolism and thromboregulation. Thrombosis has a proinflammatory component whereby biologically active substances are synthesized by different cell types that could not individually synthesize the metabolite(s). Endothelium controls platelet reactivity via at least three biochemical systems: autacoids leading to production of prostacyclin and nitric oxide (NO) and endothelial ecto-adenosine phosphatase (ADPase)/CD39/nucleoside triphosphate diphosphohydrolase (NTPDase-1). The autacoids are fluid phase reactants, not produced by tissues in the basal state, but are only synthesized intracellularly and released upon interactions of cells with an agonist. When released, they exert fleeting actions in the immediate milieu and are rapidly inactivated. CD39 is an integral component of the endothelial cell (EC) surface and is substrate activated. It maintains vascular fluidity in the complete absence of prostacyclin and NO, indicating that the latter are ancillary components of hemostasis. Therapeutic implications for the autacoids have not been compelling because of their transient and local action and limited potency. Conversely, CD39, acting solely on the platelet releasate, is efficacious in animal models. It metabolically neutralizes a prothrombotic releasate via deletion of ADP-the major recruiting agent responsible for formation of an occlusive thrombus. In addition, solCD39 reduced adenosine triphosphate (ATP)- and ischemia-induced norepinephrine release in the heart. This action can prevent fatal arrhythmia. Moreover, solCD39 ameliorated the sequelae of stroke in cd39 null mice. Thus, CD39 represents the next generation of cardioprotective and cerebroprotective molecules. This article focuses on our interpretations of recent data and their implications for therapeutics.

KEYWORDS

Thrombosis - ecto-nucleotidase - stroke - coronary artery disease - platelet function inhibitors

REFERENCES

• 1 Hellem A J. The adhesiveness of human blood platelets in vitro.  Scand J Clin Lab Invest. 1960;  12(suppl) 1-117
• 2 Gaarder A, Jonsen J, Laland S, Hellem A, Owren P A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets.  Nature. 1961;  192 531-532
• 3 Stormorken A, Paul A. Owren and the Golden Era of Haemostasis. London; Wisepress Bookshop 2001
• 4 Gaarder A, Laland S. Hypothesis for the aggregation of platelets by nucleotides.  Nature. 1964;  202 909-910
• 5 Maliszewski C R, Delespesse G J, Schoenborn M A et al.. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization.  J Immunol. 1994;  153 3574-3583
• 6 Marcus A J, Broekman M J, Drosopoulos J HF et al.. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.  J Clin Invest. 1997;  99 1351-1360
• 7 Kaczmarek E, Koziak K, Sévigny J et al.. Identification and characterization of CD39 vascular ATP diphosphohydrolase.  J Biol Chem. 1996;  271 33116-33122
• 8 Matsumoto M, Sakurai Y, Kokubo T et al.. The cDNA cloning of human placental ecto-ATP diphosphohydrolases I and II.  FEBS Lett. 1999;  453 335-340
• 9 Christoforidis S, Papamarcaki T, Galaris D, Kellner R, Tsolas O. Purification and properties of human placental ATP diphosphohydrolase.  Eur J Biochem. 1995;  234 66-74
• 10 Sévigny J, Levesque F P, Grondin G, Beaudoin A R. Purification of the blood vessel ATP diphosphohydrolase, identification and localisation by immunological techniques.  Biochim Biophys Acta. 1997;  1334 73-88
• 11 Wang T F, Guidotti G. CD39 is an ecto-(Ca²⁺,Mg²⁺)-apyrase.  J Biol Chem. 1996;  271 9898-9901
• 12 Sevigny J, Sundberg C, Braun N et al.. Differential catalytic properties and vascular topography of murine nucleoside triphosphate diphosphohydrolase 1 (NTPDase1) and NTPDase2 have implications for thromboregulation.  Blood. 2002;  99 2801-2809
• 13 Chadwick B P, Frischauf A M. Cloning and mapping of a human and mouse gene with homology to ecto-ATPase genes.  Mamm Genome. 1997;  8 668-672
• 14 Kegel B, Braun N, Heine P, Maliszewski C R, Zimmermann H. An ecto-ATPase and an ecto-ATP diphosphohydrolase are expressed in rat brain.  Neuropharmacology. 1997;  36 1189-1200
• 15 Kirley T L. Complementary DNA cloning and sequencing of the chicken muscle ecto-ATPase-homology with the lymphoid cell activation antigen CD39.  J Biol Chem. 1997;  272 1076-1081
• 16 Chadwick B P, Frischauf A M. The CD39-like gene family: Identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster.  Genomics. 1998;  50 357-367
• 17 Smith T M, Kirley T L. Cloning, sequencing, and expression of a human brain ecto-apyrase related to both the ecto-ATPases and CD39 ecto-apyrases.  Biochim Biophys Acta. 1998;  1386 65-78
• 18 Wang T F, Guidotti G. Golgi localization and functional expression of human uridine diphosphatase.  J Biol Chem. 1998;  273 11392-11399
• 19 Chadwick B P, Williamson J, Sheer D, Frischauf A M. cDNA cloning and chromosomal mapping of a mouse gene with homology to NTPases.  Mamm Genome. 1998;  9 162-164
• 20 Mulero J J, Yeung G, Nelken S T, Ford J E. CD39-L4 is a secreted human apyrase, specific for the hydrolysis of nucleoside diphosphates.  J Biol Chem. 1999;  274 20064-20067
• 21 Zimmermann H. Ectonucleotidases: some recent developments and a note on nomenclature.  Drug Dev Res. 2001;  52 44-56
• 22 Wang C J, Vlajkovic S M, Housley G D et al.. C-terminal splicing of NTPDase2 provides distinctive catalytic properties, cellular distribution and enzyme regulation.  Biochem J. 2005;  385 729-736
• 23 Marcus A J, Weksler B B, Jaffe E A, Broekman M J. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells.  J Clin Invest. 1980;  66 979-986
• 24 Koziak K, Sévigny J, Robson S C, Siegel J B, Kaczmarek E. Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes.  Thromb Haemost. 1999;  82 1538-1544
• 25 Schoenborn M A, Jenkins N A, Copeland N G et al.. Gene structure and chromosome location of mouse Cd39 coding for an ecto-apyrase.  Cytogenet Cell Genet. 1998;  81 287-289
• 26 Marcus A J, Broekman M J, Drosopoulos J HF et al.. Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.  J Pharmacol Exp Ther. 2003;  305 9-16
• 27 Marcus A J, Broekman M J, Drosopoulos J H et al.. Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1).  J Thromb Haemost. 2003;  1 2497-2509
• 28 Gayle III R B, Maliszewski C R, Gimpel S D et al.. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.  J Clin Invest. 1998;  101 1851-1859
• 29 Tran H, Anand S S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.  JAMA. 2004;  292 1867-1874
• 30 Schulman S P. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.  JAMA. 2004;  292 1875-1882
• 31 Marcus A J, Safier L B, Hajjar K A et al.. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells.  J Clin Invest. 1991;  88 1690-1696
• 32 Valles J, Santos M T, Aznar J et al.. Platelet-erythrocyte interactions enhance α_IIbβ₃ integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo.  Blood. 2002;  99 3978-3984
• 33 Valles J, Santos M T, Aznar J et al.. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity.  Circulation. 1998;  97 350-355
• 34 Handa M, Guidotti G. Purification and cloning of a soluble ATP-diphosphohydrolase (apyrase) from potato tubers (Solanum tuberosum).  Biochem Biophys Res Commun. 1996;  218 916-923
• 35 Kansas G S, Wood G S, Tedder T F. Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes.  J Immunol. 1991;  146 2235-2244
• 36 Kirley T L, Yang F, Ivanenkov V V. Site-directed mutagenesis of human nucleoside triphosphate diphosphohydrolase 3: the importance of conserved glycine residues and the identification of additional conserved protein motifs in eNTPDases.  Arch Biochem Biophys. 2001;  395 94-102
• 37 Gendron F P, Benrezzak O, Krugh B W et al.. Purine signaling and potential new therapeutic approach: possible outcomes of NTPDase inhibition.  Curr Drug Targets. 2002;  3 229-245
• 38 Schulte am Esch J, Sévigny J, Kaczmarek E et al.. Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity.  Biochemistry. 1999;  38 2248-2258
• 39 Smith T M, Lewis Carl S A, Kirley T L. Mutagenesis of two conserved tryptophan residues of the E-type ATPases: inactivation and conversion of an ecto-apyrase to an ecto-NTPase.  Biochemistry. 1999;  38 5849-5857
• 40 Kittel A, Kaczmarek E, Sévigny J et al.. CD39 as a caveolar-associated ectonucleotidase.  Biochem Biophys Res Commun. 1999;  262 596-599
• 41 Pinsky D J, Broekman M J, Peschon J J et al.. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.  J Clin Invest. 2002;  109 1031-1040
• 42 Dwyer K M, Robson S C, Nandurkar H H et al.. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation.  J Clin Invest. 2004;  113 1440-1446
• 43 Marcus A J, Broekman M J, Pinsky D J. COX inhibitors and thromboregulation.  N Engl J Med. 2002;  347 1025-1026
• 44 Marcus A J, Broekman M J, Drosopoulos J HF et al.. Thromboregulation by endothelial cells: significance for occlusive vascular diseases.  Arterioscler Thromb Vasc Biol. 2001;  21 178-182
• 45 Drosopoulos J HF, Broekman M J, Islam N et al.. Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39. Requirement of glutamate 174 and serine218 for enzyme activity and inhibition of platelet recruitment.  Biochemistry. 2000;  39 6936-6943
• 46 Drosopoulos J HF. Roles of Asp54 and Asp213 in Ca2+ utilization by soluble human CD39/ecto-nucleotidase.  Arch Biochem Biophys. 2002;  406 85-95
• 47 De Girolami U, Anthony D C, Frosch M P. The central nervous system. In: Cotran RS, Kumar V, Collins T Pathologic Basis of Disease. 6th ed. Philadelphia; W.B. Saunders 1999: 1306-1314
• 48 Caplan L R. Treatment of acute stroke: still struggling.  JAMA. 2004;  292 1883-1885
• 49 Choudhri T F, Hoh B L, Zerwes H G et al.. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.  J Clin Invest. 1998;  102 1301-1310
• 50 Choudhri T F, Hoh B L, Prestigiacomo C J et al.. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage.  J Exp Med. 1999;  190 91-99
• 51 Choudhri T F, Hoh B L, Solomon R A, Connolly Jr E S, Pinsky D J. Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice.  Stroke. 1997;  28 2296-2302
• 52 Belayev L, Khoutorova L, Deisher T A et al.. Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats.  Stroke. 2003;  34 758-763
• 53 Koch R. Research on bacteria. Presented at: 10th internationalen Medical Congress August 4-9, 1890 Berlin, Germany;
• 54 Toole J F, Sane D C, Bettermann K. Stroke prevention optimizing the response to a common threat.  JAMA. 2004;  292 1885-1887
• 55 Enjyoji K, Sévigny J, Lin Y et al.. Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.  Nat Med. 1999;  5 1010-1017
• 56 Birk A V, Bubman D, Broekman M J et al.. Role of a novel soluble nucleotide phosphohydrolase from sheep plasma in inhibition of platelet reactivity.  J Lab Clin Med. 2002;  139 116-124
• 57 Valles J, Santos M T, Marcus A J et al.. Down-regulation of human platelet reactivity by neutrophils. Participation of lipoxygenase derivatives and adhesive proteins.  J Clin Invest. 1993;  92 1357-1365
• 58 Mazer S P, Fedarau M, Liu Y L et al.. Deletion of endothelial ectoapyrase (CD39) promotes atherogenesis in hyperlipidemic mice.  Circulation. 2004;  110 79 , (abst)
• 59 Michelson A D, Furman M I. Laboratory markers of platelet activation and their clinical significance.  Curr Opin Hematol. 1999;  6 342-348
• 60 El-Omar M M, Islam N, Broekman M J et al.. The ratio of ADP-to ATP-ectonucleotidase activity is reduced in patients with coronary artery disease.  Thromb Res. 2005;  , (in press)
• 61 Wang T F, Ou Y, Guidotti G. The transmembrane domains of ectoapyrase (CD39) affect its enzymatic activity and quaternary structure.  J Biol Chem. 1998;  273 24814-24821
• 62 von Kugelgen I, Allgaier C, Schobert A, Starke K. Co-release of noradrenaline and ATP from cultured sympathetic neurons.  Neuroscience. 1994;  61 199-202
• 63 Sneddon P, Westfall T D, Todorov L D et al.. Modulation of purinergic neurotransmission.  Prog Brain Res. 1999;  120 11-20
• 64 Zimmermann H, Braun N. Ecto-nucleotidases-molecular structures, catalytic properties, and functional roles in the nervous system.  Prog Brain Res. 1999;  120 371-385
• 65 Kawashima Y, Nagasawa T, Ninomiya H. Contribution of ecto-5′-nucleotidase to the inhibition of platelet aggregation by human endothelial cells.  Blood. 2000;  96 2157-2162
• 66 Burnstock G. Current status of purinergic signalling in the nervous system.  Prog Brain Res. 1999;  120 3-10
• 67 Boehm S. ATP stimulates sympathetic transmitter release via presynaptic P2X purinoceptors.  J Neurosci. 1999;  19 737-746
• 68 Sesti C, Broekman M J, Drosopoulos J HF et al.. Ectonucleotidase in cardiac sympathetic nerve endings modulates ATP-mediated feedback of norepinephrine release.  J Pharmacol Exp Ther. 2002;  300 605-611
• 69 Benedict C R, Shelton B, Johnstone D E et al.. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.  Circulation. 1996;  94 690-697
• 70 Braunwald E, Sobel B E. Coronary blood flow and myocardial ischemia. In: Braunwald E Heart Disease, a Textbook of Cardiovascular Medicine. Philadelphia; W.B. Saunders 1988: 1191-1221